ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.90
-0.17%
US Tech 100
20,902.00
1.10%
S&P 500
6,079.33
0.49%
US Dollar vs CAD
1.40672
0.00%
Bitcoin
96,845.28
0.92%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) Share Price

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.675
-0.025
( -1.47% )
Updated: 13:26:37
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.675
Bid
1.67
Ask
1.68
Volume
14,464
1.67 Day's Range 1.695
1.22 52 Week Range 2.32
Market Cap
80.832M
Previous Close
1.70
Open
1.67
Last Trade
39
@
1.675
Last Trade Time
13:28:09
Financial Volume
US$ 24,270
VWAP
1.678
Average Volume (3m)
52,624
Shares Outstanding
48,258,111
Dividend Yield
-
PE Ratio
-1.18
Earnings Per Share (EPS)
-1.41
Revenue
9.16M
Net Profit
-68.17M

About Ikena Oncology Inc

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.ikenaoncology.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was US$1.70. Over the last year, Ikena Oncology shares have traded in a share price range of US$ 1.22 to US$ 2.32.

Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is US$82.04 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -1.18.

Ask ADVFN Intelligence (AI)

IKNA Latest News

More News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 14 2024
Edgar (US Regulatory)

Ikena Oncology Reports Third Quarter 2024 Financial Results

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided...

November 07 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 07 2024
Edgar (US Regulatory)

Ikena Oncology Reports Second Quarter 2024 Financial Results

BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an...

August 08 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

July 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 10 2024
Edgar (US Regulatory)

UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

May 28 2024
GlobeNewswire Inc.

Form 8-K - Current report

May 28 2024
Edgar (US Regulatory)

Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

May 28 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.055-3.179190751451.731.741.67580151.70453624CS
4-0.045-2.616279069771.721.791.66808361.71918288CS
12-0.015-0.8875739644971.691.791.66526241.71033506CS
26-0.085-4.829545454551.761.871.61160671.69348256CS
520.22515.51724137931.452.321.222290301.54984513CS
156-10.465-86.202635914312.1416.9491.021697713.65644909CS
260-20.725-92.522321428622.437.611.021659485.91797558CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYCNCyclerion Therapeutics Inc
US$ 7.1685
(345.25%)
119.66M
SMXSMX Security Matters Public Company
US$ 0.6185
(217.51%)
629.78M
SRMSRM Entertainment Inc
US$ 1.1049
(75.35%)
135.6M
CNEYCN Energy Group Inc
US$ 0.5221
(65.43%)
158.22M
CCRNCross Country Health
US$ 18.125
(62.41%)
8.68M
RLMDRelmada Therapeutics Inc
US$ 0.64205
(-76.82%)
15.13M
MIGIMawson Infrastructure Group Inc
US$ 0.83
(-56.54%)
11.55M
MONDMondee Holdings Inc
US$ 0.1996
(-32.36%)
2.92M
ORISOriental Rise Holdings Ltd
US$ 8.58
(-28.20%)
570.72k
FGLFounder Group Limited
US$ 3.02
(-25.98%)
10.08M
SMXSMX Security Matters Public Company
US$ 0.6185
(217.51%)
629.78M
SVMHSRIVARU Holding Ltd
US$ 0.0272
(23.64%)
453.09M
HTOOFusion Fuel Green PLC
US$ 0.488
(53.46%)
272.1M
CNEYCN Energy Group Inc
US$ 0.5221
(65.43%)
158.22M
NVDANVIDIA Corporation
US$ 145.285
(3.58%)
151.04M

IKNA Discussion

View Posts
Monksdream Monksdream 2 months ago
IKNA under $2
👍️0
Monksdream Monksdream 4 months ago
IKNA under $2
👍️0
Monksdream Monksdream 5 months ago
IKNA under $2
👍️0
Monksdream Monksdream 5 months ago
IKNA under $2
👍️0
glenn1919 glenn1919 6 months ago
IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
IKNA under $2=
👍️0
Monksdream Monksdream 9 months ago
IKNA under $2
👍️0
herbied47 herbied47 1 year ago
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 1 year ago
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 1 year ago
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 1 year ago
what happened here my short friend
👍️0
Tacostocks Tacostocks 1 year ago
Aged like milk eh
👍️0
AJ Freely AJ Freely 1 year ago
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 2 years ago
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA monster
👍️0
crudeoil24 crudeoil24 4 years ago
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

Your Recent History

NASDAQ
IKNA
Ikena Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved